Nat Commun: New antibodies help to meddle SARS-Cov-2 virus infection.

AUGUST 26, 2020 /--- -- A new study published recently in the journal Nature Communications by researchers at the University of Massachusetts School of Medicine suggests that COVID19-specific IgA monoclonal antibodies may provide effective immunity to new coronavirus in the respiratory system, a potentially key feature in determining vaccine effectiveness. Dr. Yang Wang, author of the
article, and colleagues described the characteristics of monoclonal antibodies (MABs) that cross-react against SARS-CoV-2 prickly proteins, suggesting that blocking the binding of ACE2 subjects to respiratory mucous membrane tissue may prevent or limit SARS-CoV-2 infections that cause COVID-19 disease.
(Photo: www.pixabay.com) When SARS-CoV-2 was first discovered, researchers realized that monoclonal antibodies might help fight the infection.
they retrieved frozen hybrid tumor cells developed 16 years ago and looked at whether the antibody molecules designed to fight Sars were equally effective against the new coronavirus.
"We are pleased to find that IgA-type SARS-CoV-2 antibodies bind and locally to the virus more effectively than circulating IgG antibodies."
in nature, IgA antibodies cover mucous membrane surfaces such as the respiratory tract, gastrointestinal tract, and gudo, where they are stabilized by the mucus layer on those surfaces.
, they play an important role in preventing pathogens from binding to host cells, thus preventing infection.
results, the researchers further explored the nature of IGA antibody action.
Schiffer and Hou found that MAb362 has a highly similar framework to MAb 80R, a SARS-CoV antibody whose crystal structure is parsed.
molecular model reveals the highly conservative characteristics of the subject binding domain of the S protein.
, MAb362 mediated the SARS-CoV-2 virus by directly competing for the combination of the S protein with the hACE2 receptor.
(bioon.com) Source: Researchers discover antibodies that may protect against COVID-19 Original source: Monir Ejemel et al. A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 Spike-ACE2 interaction, Nature Communications (2020). DOI: 10.1038/s41467-020-18058-8.